116 related articles for article (PubMed ID: 27067776)
21. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
22. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
23. First off-time treatment prostate-specific antigen kinetics predicts survival in intermittent androgen deprivation for prostate cancer.
Sanchez-Salas R; Olivier F; Prapotnich D; Dancausa J; Fhima M; David S; Secin FP; Ingels A; Barret E; Galiano M; Rozet F; Cathelineau X
Prostate; 2016 Jan; 76(1):13-21. PubMed ID: 26498916
[TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
25. Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status.
Wu J; Lin G; Zhu Y; Zhang H; Shi G; Shen Y; Zhu Y; Dai B; Ye D
Sci Rep; 2017 Aug; 7(1):8869. PubMed ID: 28827755
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy.
Ren GF; Tang L; Yang AQ; Jiang WW; Huang YM
Histol Histopathol; 2014 Apr; 29(4):535-42. PubMed ID: 24222185
[TBL] [Abstract][Full Text] [Related]
27. The Utility of Serum CA9 for Prognostication in Prostate Cancer.
Smith AD; Truong M; Bristow R; Yip P; Milosevic MF; Joshua AM
Anticancer Res; 2016 Sep; 36(9):4489-92. PubMed ID: 27630286
[TBL] [Abstract][Full Text] [Related]
28. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.
Babasaki T; Sentani K; Sekino Y; Kobayashi G; Thang Pham Q; Katsuya N; Akabane S; Taniyama D; Hayashi T; Shiota M; Oue N; Teishima J; Matsubara A; Yasui W
Cancer Med; 2021 Aug; 10(16):5574-5588. PubMed ID: 34240817
[TBL] [Abstract][Full Text] [Related]
30. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer.
Ekici S; Cerwinka WH; Duncan R; Gomez P; Civantos F; Soloway MS; Lokeshwar VB
Int J Cancer; 2004 Oct; 112(1):121-9. PubMed ID: 15305383
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
34. The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases.
O'Hurley G; Prencipe M; Lundon D; O'Neill A; Boyce S; O'Grady A; Gallagher WM; Morrissey C; Kay EW; Watson RW
Prostate; 2014 Feb; 74(3):306-13. PubMed ID: 24249383
[TBL] [Abstract][Full Text] [Related]
35. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
36. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
Yashi M; Nishihara D; Mizuno T; Yuki H; Masuda A; Kambara T; Betsunoh H; Abe H; Fukabori Y; Muraishi O; Kamai T
Clin Genitourin Cancer; 2014 Oct; 12(5):e197-203. PubMed ID: 24674784
[TBL] [Abstract][Full Text] [Related]
37. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
[TBL] [Abstract][Full Text] [Related]
38. Prognostication of OCT4 isoform expression in prostate cancer.
de Resende MF; Chinen LT; Vieira S; Jampietro J; da Fonseca FP; Vassallo J; Campos LC; Guimarães GC; Soares FA; Rocha RM
Tumour Biol; 2013 Oct; 34(5):2665-73. PubMed ID: 23636800
[TBL] [Abstract][Full Text] [Related]
39. C-Reactive Protein is a Prognostic Marker for Patients with Castration-Resistant Prostate Cancer.
Liao SG; Cheng HH; Lei Y
Oncol Res Treat; 2016; 39(5):266-71. PubMed ID: 27174032
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical Expression of the Pluripotency Factor OCT4 in Canine Mast Cell Tumours.
Vargas TH; Pulz LH; Barra CN; Kleeb SR; Xavier JG; Catão-Dias JL; Fukumasu H; Nishiya AT; Strefezzi RF
J Comp Pathol; 2015 Nov; 153(4):251-5. PubMed ID: 26460092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
